Mesothelin-Expressing TumorsPhase 1NCT06623396Papers
M28z1XXPD1DNR CAR
Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
What the film says
This trial is for adults with metastatic or unresectable HER2 negative breast cancer.
The idea: combine two immunotherapy drugs, CDX-1140, a CD40 agonist given by vein, and CDX-301, a Flt3 ligand given as injections under the skin, with standard pegylated liposomal doxorubicin chemotherapy.
This phase 1 study plans 30 patients and looks at dose limiting side effects and a safe dose and schedule. At UT Southwestern Medical Center in Dallas, Sangeetha Reddy leads it.
Public record; not medical advice.
Sources behind this film
Adults; unresectable stage III or IV HER2 negative breast cancer; CDX-1140 CD40 agonist IV; CDX-301 Flt3 ligand subcutaneous; with PLD; Phase 1; 30 patients; DLT; safe dose and schedule; UT Southwestern, Dallas; Sangeetha Reddy
The drug
CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.
CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.
The immunotherapy drugs CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment PLD work by kickstarting the immune response against cancer cells. CDX-301 increases the antigen presenting immune cells needed to kickstart the immune response, CDX-1140 activates these cells, and chemotherapy helps release antigens from the cancer cells to train these antigen presenting immune cells to recognize the cancer for the immune system to attack it.
The study
This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer, and to determine a safe dose and treatment schedule of the three drugs.
This research study will also test how your immune system responds to these treatments alone and in combination.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.